{"title":"社会因素可能会限制PCSK9抑制剂的成功，PCSK9抑制剂是他汀类药物不耐受患者高脂血症的有效治疗方法","authors":"Abigail C. Kuplicki","doi":"10.22237/crp/1698019740","DOIUrl":null,"url":null,"abstract":"A clinical decision report using: Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol. 2015;9(6):758-769. https://doi.org/10.1016/j.jacl.2015.08.006 for a statin-intolerant patient with hyperlipidemia.","PeriodicalId":10422,"journal":{"name":"Clinical Research In Practice: The Journal of Team Hippocrates","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Social determinants may limit the success of PCSK9 inhibitors, an effective treatment for hyperlipidemia in statin-intolerant patients\",\"authors\":\"Abigail C. Kuplicki\",\"doi\":\"10.22237/crp/1698019740\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A clinical decision report using: Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol. 2015;9(6):758-769. https://doi.org/10.1016/j.jacl.2015.08.006 for a statin-intolerant patient with hyperlipidemia.\",\"PeriodicalId\":10422,\"journal\":{\"name\":\"Clinical Research In Practice: The Journal of Team Hippocrates\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research In Practice: The Journal of Team Hippocrates\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22237/crp/1698019740\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research In Practice: The Journal of Team Hippocrates","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22237/crp/1698019740","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Social determinants may limit the success of PCSK9 inhibitors, an effective treatment for hyperlipidemia in statin-intolerant patients
A clinical decision report using: Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol. 2015;9(6):758-769. https://doi.org/10.1016/j.jacl.2015.08.006 for a statin-intolerant patient with hyperlipidemia.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
